Step Into a World of Imagination With The Newly-Renovated Thematic Rooms at Four Points Surabaya, Pakuwon Indah
The new addition features six uniquely designed rooms, where each of the room designed to delight the little guests' fantasy to life through carefully curated interiors, interactive design elements, and playful atmospheres that spark joy and creativity. Whether it's a magical escape or an adventurous journey, these rooms are built to inspire unforgettable memories.
Introducing the Six Thematic Rooms:
Strategically located above the Pakuwon Mall, the largest shopping mall in Indonesia, Four Points by Sheraton Surabaya, Pakuwon Indah provides the perfect balance of leisure and convenience, moreover enhanced by these imaginative new room options. For reservations and more information, visit https://www.marriott.com/subfk or contact at +6231.297.10000
Press Contact
Ms. Cindy Yuwono
Complex Marketing Communications Manager
fp.subfk.marcomm@fourpoints.com
Four Points by Sheraton is a global brand with over 335 hotels in over 45 countries and territories. At Four Points, travel is reinvented where timeless classics are woven with modern details, paired with genuine service in a casual environment—all around the world. Four Points hotels can be found in the heart of urban centers, near the beach, by the airport, or in the suburbs. Each hotel offers a familiar place to kick back and relax with an authentic sense of the local, where guests can watch sports and enjoy the brand's Best Brews® program. Four Points is proud to participate in Marriott Bonvoy®, the global travel program from Marriott International. The program offers members an extraordinary portfolio of global brands, exclusive experiences on Marriott Bonvoy Moments and unparalleled benefits including free nights and Elite status recognition. To enroll for free or for more information about the program, visit marriottbonvoy.com. To learn more about Four Points, visit us online.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
4 days ago
- Korea Herald
Rebellions Announces Collaboration with Marvell to Deliver Custom AI Infrastructure for Sovereign-Scale Deployments
SEOUL, South Korea, July 29, 2025 /PRNewswire/ -- Rebellions Inc., a leading AI semiconductor company based in South Korea, today announced a collaboration with Marvell Technology, Inc. (NASDAQ: MRVL) to offer high-performance, energy-efficient AI systems tailored for regionally driven and sovereign-backed AI initiatives across APAC and the Middle East. As AI infrastructure becomes increasingly central to national competitiveness, a shift is underway from standardized, GPU-based architectures toward domain-specific systems built around custom ASICs. This change is being driven not only by global hyperscalers, but also by sovereign-backed initiatives and regional cloud providers seeking infrastructure that delivers scalability, efficiency, and control. This collaboration will enable Rebellions to design customer-specific AI accelerators utilizing Marvell® custom platforms—leveraging advanced packaging, high-speed SerDes and die-to-die interconnects resulting in a tightly integrated, end-to-end rack solution built for high-performance, energy-efficient AI inference at scale. "AI infrastructure is undergoing a fundamental shift—organizations are no longer settling for one-size-fits-all solutions," said Sunghyun Park, CEO of Rebellions. "By collaborating with Marvell, we're combining deep expertise in AI chip design with cutting-edge silicon integration to deliver custom AI infrastructure designed to meet the real-world needs of sovereign entities." "Custom AI infrastructure is key to unlocking the next wave of data center innovation," said Will Chu, Senior Vice President and General Manager of Custom Cloud Solutions at Marvell. "We look forward to collaborating with Rebellions to offer next-generation custom AI infrastructure tailored for performance, efficiency and scalability." About Rebellions Rebellions develops AI accelerators optimized for Large Language Models and large-scale inference, delivering industry-leading energy efficiency. Its flagship chip REBEL uses chiplet architecture and 144GB HBM3E memory for massive-scale AI inference. The platform includes software for seamless data center integration. Building on its AI accelerator ATOM's proven mass-production experience since 2024, Rebellions is now backed by strategical investors including SK Telecom, SK hynix, Aramco's Wa'ed Ventures, and KT. Strengthened by its merger with SK SAPEON, Rebellions is Asia's leading independent AI semiconductor platform. Marvell and the M logo are trademarks of Marvell or its affiliates. Please visit for a complete list of Marvell trademarks. Other names and brands may be claimed as the property of others. This press release contains forward-looking statements within the meaning of the U. S. federal securities laws that involve risks and uncertainties. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future events, results or achievements. Actual events, results or achievements may differ materially from those contemplated in this press release. Forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict, Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and no person assumes any obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Korea Herald
4 days ago
- Korea Herald
Winners in Second Annual Stevie® Awards for Technology Excellence Announced
Winners to Be Celebrated at a Ceremony in New York on September 16 FAIRFAX, Va., July 29, 2025 /PRNewswire/ -- Winners in the 2025 (second annual) Stevie® Awards for Technology Excellence were announced today. The awards celebrate the remarkable accomplishments of individuals, teams, and organizations shaping the future of technology across all industry sectors. Individuals and organizations worldwide are eligible to enter - public and private, for-profit and non-profit, large and small. Among the organizations with multiple Stevie Award wins are Amazon / Amazon Web Services (27), Meta (19), Cisco (14), IBM (12), Microsoft (9), Walmart (8), JPMorganChase (7), Salesforce (7), Cognizant (6), Google (6), Gov2Biz Inc (6), Oracle (6), Alliant (5), Apple (5), BostonGene (5), Encora (5), and Epique Realty (5). For a full list of winners by category, visit Winners will be celebrated during a gala awards banquet on Tuesday, September 16 at the Marriott Marquis Hotel in New York City. Tickets are now on sale. The presentations will be broadcast live. More than 1,500 nominations from organizations in 36 nations and territories were evaluated in this year's competition. Winners were determined by the average scores of more than 160 professionals worldwide, acting as judges. The Stevie Awards for Technology Excellence recognize achievement in many facets of the workplace. Categories are grouped in 20 technology-industry sections: The awards are presented by the Stevie Awards, organizer of nine of the world's leading business awards shows including the prestigious International Business Awards® and American Business Awards®. About the Stevie Awards Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, the Stevie Awards for Technology Excellence, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at .
Korea Herald
5 days ago
- Korea Herald
Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug
SHANGHAI and HONG KONG, July 28, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the China National Medical Products Administration (NMPA) has approved XPOVIO ® (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy, a new indication of XPOVIO ®. This approval for XPOVIO ® is based on the data of the BENCH trial, a randomized, controlled, open-label, multicenter Phase III bridging study which compared the safety and efficacy of XVd and Vd regimens in 154 Chinese patients with R/R MM who have received one to three prior lines of therapy. The efficacy and safety data of the BENCH study are generally consistent with those from the global, multicenter, Phase III BOSTON study and met the objectives of the bridging study which showed: Clear superiority of the XVd regimen: compared to the Vd regimen, the XVd regimen demonstrated better clinical efficacy, longer PFS and DOR, a higher ORR, a higher rate of very good partial response (VGPR) or deeper responses and minimal residual disease (MRD) negativity, as well as a trend of prolonged OS. Notable clinical benefits for elderly patients: the study observed particularly notable efficacy in the cohort of elderly patients aged ≥65, validating XPOVIO ® as a better treatment option for this patient population. Prof. Jin Lu, principal investigator of the BENCH study from Peking University People ' s Hospital, said, "MM is the second most common hematologic malignancy. The clinical application of autologous hematopoietic stem cell transplantation (ASCT) and novel agents in the first-line setting have resulted in longer overall survival for patients. However, the condition remains incurable with most patients end up relapsing. As a novel inhibitor of the nuclear export protein that adopts a novel mechanism of action, selinexor was proven by the BENCH study to be significantly efficacious in Chinese patients with MM. This approval for XPOVIO ® is a great news for patients with R/R MM, especially those relapsing for the first time." Prof. Jian Hou, principal investigator of the BENCH study from Shanghai Jiaotong University School of Medicine Affiliated Renji Hospital, commented, "The incidence of MM has been steadily rising year after year. According to the Globocan statistics for 2022, there were 30,300 new cases of MM and 18,662 MM related deaths in China, a figure that highlights an urgent unmet clinical need. Selinexor in combination with bortezomib and dexamethasone incorporates a unique mechanism of action and demonstrated significant efficacy. Moreover, XPOVIO ® does not require intravenous administration, therefore provides clinicians a new treatment strategy that can effectively reduce burden on patients." With a novel mechanism of action, XPOVIO ® is the world's first approved orally-available, selective XPO1 inhibitor, which has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea). While bringing XPOVIO ® to more APAC markets, Antengene is also striving to expand the indications of XPOVIO ®. Leveraging the drug's novel mechanism of action, Antengene is currently developing multiple combination regimens of XPOVIO ® for the treatment of various indications including myelofibrosis (MF) and endometrial cancer. About Antengene Antengene Corporation Limited ("Antengene", SEHK: is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO ® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact:
